60 Degrees Pharmaceuticals, Inc. (SXTP)
60 Degrees Pharmaceuticals, Inc.
1025 Connecticut Avenue NW
Suite 1000
Washington, DC 20036
United States
202-327-5422
https://www.60degreespharma.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 3
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Geoffrey Stuart Dow | Chairman, CEO & President | 125.56k | N/D | 1974 |
| Mr. Tyrone Miller | CFO & Treasurer | 135.63k | N/D | 1975 |
| Dr. Bryan Smith | Chief Medical Officer | N/D | N/D | 1966 |
| Ms. Kristen Landon | Chief Commercial Officer | N/D | N/D | 1967 |
| Ms. Jennifer Herz | Director | N/D | N/D | N/D |
Descripción
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is headquartered in Washington, the District of Columbia.
Gestión corporativa
La calificación ISS Governance QuickScore de 60 Degrees Pharmaceuticals, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
